BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 33012523)

  • 1. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
    Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
    Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An miRNA signature associated with tumor mutation burden in endometrial cancer.
    Zhou H; Chen L; Qin M; Lei Y; Li T; Li H; Cheng X
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33141168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
    Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
    Front Immunol; 2021; 12():788431. PubMed ID: 34970268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
    Zhang C; Li Z; Qi F; Hu X; Luo J
    Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
    Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
    Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer.
    Lu N; Liu J; Ji C; Wang Y; Wu Z; Yuan S; Xing Y; Diao F
    Bioengineered; 2021 Dec; 12(1):3603-3620. PubMed ID: 34252354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
    Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
    Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
    Lin J; Lin Y; Huang Z; Li X
    Comput Math Methods Med; 2020; 2020():8836493. PubMed ID: 33273963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma.
    Zhao L; Fu X; Han X; Yu Y; Ye Y; Gao J
    Cancer Cell Int; 2021 Jan; 21(1):80. PubMed ID: 33509222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying
    Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
    PeerJ; 2023; 11():e16618. PubMed ID: 38099311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
    Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
    Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
    Sun XX; Wen HQ; Zhan BX; Yang P
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel risk score system of immune genes associated with prognosis in endometrial cancer.
    Zhou H; Zhang C; Li H; Chen L; Cheng X
    Cancer Cell Int; 2020; 20():240. PubMed ID: 32549787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma.
    Zhang C; Shen L; Qi F; Wang J; Luo J
    J Cell Physiol; 2020 Apr; 235(4):3849-3863. PubMed ID: 31596511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
    Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
    Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
    [No Abstract]   [Full Text] [Related]  

  • 18. Cuproptosis-Associated lncRNA Gene Signature Establishes New Prognostic Profile and Predicts Immunotherapy Response in Endometrial Carcinoma.
    Jiang XY; Hu JJ; Wang R; Zhang WY; Jin QQ; Yang YT; Mei J; Hong L; Yao H; Tao F; Li JJ; Liu Y; Zhang L; Chen SX; Chen G; Song Y; Zhou SG
    Biochem Genet; 2023 Dec; ():. PubMed ID: 38108937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
    Wang Z; Xing L; Huang Y; Han P
    Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of a tumor mutation burden-related signature combined with immune microenvironment infiltration in adrenocortical carcinoma.
    Luo Y; Chen Q; Lin J
    Math Biosci Eng; 2022 May; 19(7):7055-7075. PubMed ID: 35730296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.